Following our ground-breaking proof of concept data, significant progress has been made to refine and optimise our process technology, improving yield, efficiency, potency and purity, and build a robust preclinical safety data package to the high level required to gain regulatory authorisation to enter first-in-man clinical trials. We are currently finalising our clinical protocol and hope to be in the clinic within 18-24 months. Further details will be uploaded to our website and social media accounts but for more information, please contact clinicaltrials@rinri-therapeutics.com
